Shots:

• The first patient has been enrolled in a P-IIb clinical trial to evaluate the safety and efficacy of suvecaltamide vs PBO in 400 adults aged 18 to 80yrs. with moderate to severe ET across 50+ trial sites in the US, UK, and the EU
• The primary efficacy EPs of the trial is the change from baseline @12wks. on the TETRAS composite outcome score representing the components from the TETRAS-activities of daily living and TETRAS-performance subscale, and measures the functional impact due to tremor. The results are expected in H1’24
• Suvecaltamide (JZP385) is a highly selective modulator of T-type calcium channels which is currently in development for the treatment of moderate to severe ET

Ref: PR Newswire | Image: Jazz